Topical vitamin D analogues alone or in association with topical steroids for psoriasis: A systematic review

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue SUPPL. 3, 2012, Pages 52-60

  Devaux, S ^a   Castela, A ^b   Archier, E ^c   Gallini, A ^d   Joly, P ^e   Misery, L ^f   Aractingi, S ^g   Aubin, F ^h   Bachelez, H ⁱ   Cribier, B ^j   Jullien, D ^k   Le Maitre M ^l   Richard, M A ^c   Ortonne, J P ^b   Paul, C ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d Faculté de Médecine Centre Hospitalo universitaire   (France)

^e UNIVERSITÉ DE ROUEN   (France)

^f BREST UNIVERSITY HOSPITAL   (France)

^g HÔPITAL TENON   (France)

^h UNIVERSITÉ DE FRANCHE COMTÉ   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k EDOUARD HERRIOT HOSPITAL   (France)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL; HYDROCORTISONE; PIMECROLIMUS; STEROID; TACALCITOL; TACROLIMUS; ULOBETASOL PROPIONATE;

COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; HYPERCALCEMIA; MONOTHERAPY; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; SKIN ATROPHY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; PSORIASIS; QUALITY OF LIFE; RECURRENCE; VITAMIN D;

EID: 84860125404     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04524.x     Document Type: Review

References (62)

1. Schäfer T,. Epidemiology of psoriasis. Review and the German perspective. Dermatology (Basel) 2006; 212: 327-337.
2. Barker J,. Skin diseases with high public health impact. Psoriasis. Eur J Dermatol 2007; 17: 563-564.
3. Cather J, Menter A,. Novel therapies for psoriasis. Am J Clin Dermatol 2002; 3: 159-173. (Pubitemid 34533776)
4. Paul C, Gallini A, Archier E, et al. Evidence-based recommendations on topical treatments and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. (J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 1-10.
5. Long CC, Mills CM, Finlay AY,. A practical guide to topical therapy in children. Br J Dermatol 1998; 138: 293-296. (Pubitemid 28114134)
6. Ortonne J-P, Noerrelund KL, Papp K, et al. Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body. Eur J Dermatol 2010; 20: 585-589.
7. Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010; 20: 465-471.
8. Menter A, Abramovits W, Colõn LE, Johnson LA, Gottschalk RW,. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol 2009; 8: 52-57.
9. Saraceno R, Andreassi L, Ayala F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat 2007; 18: 361-365. (Pubitemid 350223199)
10. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-1160. (Pubitemid 43727399)
11. Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology (Basel) 2006; 213: 319-326. (Pubitemid 44837020)
12. White S, Vender R, Thaçi D, et al. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. Am J Clin Dermatol 2006; 7: 177-184. (Pubitemid 43845342)
13. Peeters P, Ortonne J-P, Sitbon R, Guignard E,. Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology (Basel) 2005; 211: 139-145. (Pubitemid 41160250)
14. Lahfa M, Mrowietz U, Koenig M, Simon JC,. Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis. Eur J Dermatol 2003; 13: 261-265. (Pubitemid 36683435)
15. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology (Basel) 2002; 205: 389-393. (Pubitemid 35356768)
16. Guenther L, Van de Kerkhof PCM, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316-323.
17. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82: 131-135. (Pubitemid 34596689)
18. Singh S, Reddy DC, Pandey SS,. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks. J Am Acad Dermatol 2000; 1: 61-65. (Pubitemid 30439714)
19. Ortonne J-P,. Nouvelle modalité thérapeutique par le calcipotriol plus le dipropionate de bétaméthasone. Nouv Dermatol 1995; 14: 746-751.
20. Ruzicka T, Lorenz B,. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol 1998; 138: 254-258. (Pubitemid 28114127)
21. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150: 1167-1173. (Pubitemid 38932288)
22. Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998; 139: 649-654. (Pubitemid 28474311)
23. Lebwohl M, Yoles A, Lombardi K, Lou W,. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998; 39: 447-450. (Pubitemid 28417383)
24. Highton A, Quell J,. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. J Am Acad Dermatol 1995; 32: 67-72.
25. Zhu X, Wang B, Zhao G, et al. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 μg/g ointment vs. calcipotriol 50 μg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol 2007; 21: 466-472. (Pubitemid 46454898)
26. Camarasa JM, Ortonne J-P, Dubertret L,. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat 2003; 14: 8-13. (Pubitemid 36417421)
27. Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB,. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol 1997; 137: 581-586. (Pubitemid 27469510)
28. Bourke JF, Iqbal SJ, Hutchinson PE,. A randomized double-blind comparison of the effects on systemic calcium homeostasis of topical calcitriol (3 μg/g) and calcipotriol (50 μg/g) in the treatment of chronic plaque psoriasis vulgaris. Acta Derm Venereol 1997; 77: 228-230. (Pubitemid 27240196)
29. Molin L, Cutler TP, Helander I, Nyfors B, Downes N,. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. Br J Dermatol 1997; 136: 89-93. (Pubitemid 27016181)
30. Pariser DM, Pariser RJ, Breneman D, et al. Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study. Arch Dermatol 1996; 132: 1527. (Pubitemid 26424568)
31. Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P,. Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double-blind, placebo-controlled study. Acta Derm Venereol 1993; 73: 300-304. (Pubitemid 23282979)
32. Cunliffe WJ, Berth-Jones J, Claudy A, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992; 26: 736-743.
33. Harrington CI, Goldin D, Lovell LR, et al. Comparative effects of two different calcipotriol (MC 903) cream formulations versus placebo in psoriasis vulgaris. A randomised, Double-Blind, Placebo-Controlled, Parallel Group Multi-Center Study. J Eur Acad Dermatol Venereol 1996; 6: 152-158.
34. Langner A, Stapõr W, Ambroziak M,. Efficacy and tolerance of topical calcitriol 3 μg/g in psoriasis treatment: a review of our experience in Poland. Br J Dermatol 2001; 144 (Suppl 58): 11-16.
35. Lebwohl M, Menter A, Weiss J, et al. Calcitriol 3 μg/g ointment in the management of mild to moderate plaque type psoriasis: results from two placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2007; 6: 428-435.
36. Van de Kerkhof PCM,. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol 2004; 151: 663-668. (Pubitemid 39330893)
37. Ortonne JP, Ganslandt C, Tan J, Nordin P, Kragballe K, Segaert S,. Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. J Eur Acad Dermatol Venereol 2009; 23: 919-926.
38. Blum R, Schwartzel E, Siskin S, Epinette WW,. Evaluating the safety of calcipotriene 30 g per day in patients with psoriasis: a parallel group, vehicle-controlled study. J Clin Pharmacol 1998; 38: 368-372. (Pubitemid 28194178)
39. Guzzo C, Lazarus G, Goffe BS, Katz HI, Lowe NJ, Pincus SH,. Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis. J Am Acad Dermatol 1996; 34: 429-433. (Pubitemid 26083819)
40. Rizova E, Corroller M,. Topical calcitriol-studies on local tolerance and systemic safety. Br J Dermatol 2001; 144 (Suppl 58): 3-10.
41. Sips AJ, Netelenbos JC, Barto R, Verburgh CA, Nieboer C, Van der Vijgh WJ,. Topically applied low-dose calcitriol has no calciotropic effect in patients with stable plaque psoriasis. J Am Acad Dermatol 1994; 30: 966-969. (Pubitemid 24166564)
42. Traulsen J, Hughes-Formella BJ,. The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment. Dermatology (Basel) 2003; 207: 166-172. (Pubitemid 37034346)
43. Fleming C, Ganslandt C, Leese GP,. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris. J Drugs Dermatol 2010; 9: 969-974.
44. Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S,. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol 2009; 161: 159-166.
45. Van de Kerkhof PCM, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009; 160: 170-176.
46. Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology (Basel) 2008; 217: 321-328.
47. Buckley C, Hoffmann V, Shapiro J, Saari S, Cambazard F, Milsgaard M,. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology (Basel) 2008; 217: 107-113.
48. Jemec GBE, Ganslandt C, Ortonne J-P, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2008; 59: 455-463.
49. Reygagne P, Mrowietz U, Decroix J, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat 2005; 16: 31-36. (Pubitemid 40283322)
50. Duweb GA, Abuzariba O, Rahim M, al-Taweel M, Abdulla SA,. Scalp psoriasis: topical calcipotriol 50 μg/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res 2000; 20: 65-68. (Pubitemid 32289621)
51. Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994; 130: 483-487. (Pubitemid 24204668)
52. Klaber MR, Hutchinson PE, Pedvis-Leftick A, et al. Comparative effects of calcipotriol solution (50 μg/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 1994; 131: 678-683. (Pubitemid 24344055)
53. Kreuter A, Sommer A, Hyun J, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006; 142: 1138-1143. (Pubitemid 44414397)
54. Liao YH, Chiu HC, Tseng YS, Tsai TF,. Comparison of cutaneous tolerance and efficacy of calcitriol 3 μg/g ointment and tacrolimus 0.3 mg/g ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 2007; 157: 1005-1012. (Pubitemid 47583535)
55. Koo J, Blum RR, Lebwohl M,. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol 2006; 55: 637-641. (Pubitemid 44436646)
56. Farber EM, Bright RD, Nall ML,. Psoriasis. A questionnaire survey of 2144 patients. Arch Dermatol 1968; 98: 248-259.
57. Farber EM, Nall ML,. The natural history of psoriasis in 5600 patients. Dermatologica 1974; 148: 1-18.
58. Van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV,. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology (Basel) 1998; 197: 326-334. (Pubitemid 29000784)
59. Feldman SR, Housman TS,. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003; 4: 221-224. (Pubitemid 36506427)
60. Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA,. Adherence in the treatment of psoriasis: a systematic review. Dermatology [Internet]. 2011 juill 13 [cité 2011 sept 2]; Available from
61. Claxton AJ, Cramer J, Pierce C,. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310. (Pubitemid 32804122)
62. Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003; 120: 738-741. (Pubitemid 36529071)